ClinicalTrials.gg
CompletedNCT06188039PRESCIENCEUpdated Jan 6, 2026

Superior Vena Cava Collapsibility Index for Predicting Fluid Responsiveness During High-risk Non-cardiac Surgery

An interventional study of Superior vena cava collapsibility index and PEEP elevation in Surgery, Fluid Responsiveness and Transesophageal Echocardiography, sponsored by Uniwersytecki Szpital Kliniczny w Opolu. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Uniwersytecki Szpital Kliniczny w Opolu · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective study is to validate the superior vena cava collapsibility index (SVC-CI) as a predictor of fluid responsiveness during laparotomy and open aortic surgery. The SVC-CI and patients' response to fluid will be assessed based on transesophageal echocardiography.

The study has three arms, in order to validate SVC-CI under the conditions of laparotomy, aortic cross clamping and high PEEP levels. One of the study arms will be an active comparator arm.

The data obtained from this study may help physicians guide intraoperative fluid therapy in a more efficient manner, in order to decrease perioperative mortality.

Read the detailed description

Patients undergoing high-risk non-cardiac surgery, including acute laparotomies and open aortic surgery, are at high risk of postoperative complications and adverse cardiovascular events. Perioperative fluid therapy is a factor which is strongly associated with postoperative outcomes. To avoid both hypovolemia and excessive fluid administration a strategy of goal-directed fluid therapy (GDFT) has been coined. Traditionally in the setting of operating rooms GDFT relied on stroke-volume variation (SVV) measured by hemodynamic monitors, based on uncalibrated pulse contour cardiac output analysis (uAPCO). However in the described cohort of patients uAPCO methods show a significantly increased measurement error, which is mainly attributed to dynamic changes in peripheral vascular tone. Furthermore, frequent occurrence of arhytmias in those patients limits the use of SVV and all other dynamic indices of fluid responsiveness based on those methods. Superior vena cava collapsibility index (SVC-CI) is a parameter which is devoid of the above mentioned limitations. It relies on respiratory variation of superior vena cava during the respiratory cycle and is therefore reliable in patients with irregular heart rhytm and seems independent from changing afterload conditions.

The main purpose of this study is to validate SVC-CI in patients undergoing controlled mechanical ventilation during laparotomies and during open aortic surgery, with focus on elevated PEEP levels and aortic cross-clamping.

02

Conditions studied

  • Surgery
  • Fluid Responsiveness
  • Transesophageal Echocardiography

Keywords

  • Fluid responsiveness
  • non-cardiac surgery
  • Superior vena cava collapsibility index
  • echocardiography
03

In context

Lead sponsor

Uniwersytecki Szpital Kliniczny w Opolu is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF ( form)
  • Age > 18 years old Eligibility criteria for each arm (additionally to mandatory criteria)
  • Arm 1 - Patients undergoing open aortic surgery
  • Arm 2 - Patients undergoing laparotomy
  • Arm 3 - Patients undergoing laparotomy with sinus rhytm

Exclusion criteria

Exclusion Criteria:

  1. Patients who are deemed to be at risk of harm due to excessive fluid administration:

    • End-stage renal disease ( \<15ml/kg/min)
    • Decompensated heart failure
    • Respiratory failure prior to surgery
    • Other cases where the risk of harm from fluid overload is assessed to be significant by the investigator
  2. Medical to the use of transesophageal echocardiography:

    • Active ulcerative gastritis or bleeding from upper gastrointestinal tract
    • Past history of esophageal or gastric surgery
    • Esophageal varices or other esophageal disease (stricture, Barret's disease, perforation in the past, achalasia)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Patients undergoing open aortic surgery with sinus rhythm

    Arm to validate SVC-CI during open aortic surgery with special focus of predicting FR during aortic cross clamping (n=50).

    Diagnostic Test: Superior vena cava collapsibility index

  • Experimental
    Patients undergoing laparotomy and high PEEP

    Arm designed to validate SVC-CI during laparotomy, ventilated with high PEEP levels (8-10cmH2O). PEEP will be raised transiently during measurements (n=50).

    Diagnostic Test: Superior vena cava collapsibility index · Other: PEEP elevation

  • Active comparator
    Patients undergoing laparotomy with standard ventilatory settings

    Arm designed as an active comparator with standard (protective) ventilatory settings (n=50). Tidal volumes (Vt) will be set for 8ml/kg.

    Diagnostic Test: Superior vena cava collapsibility index

Interventions

  • Diagnostic testSuperior vena cava collapsibility index

    After induction of general anaesthesia following interventions will be performed. 1. Insertion of a tranesophageal echocardiography probe 2. Measurement of SVC-CI 3. Measurement of LVOT-VTI prior to fluid bolus 4. Fluid bolus (250ml of crystalloid) 5. Measurement of LVOT-VTI after fluid bolus Several volume trials per patient will be allowed, until safety criteria are met. In such cases further testing will be stopped.

    Also known as: SVC-CI, fluid bolus, transesophageal echocardiography

  • OtherPEEP elevation

    A transient elevation of positive end-expiratory pressure (PEEP) will be applied, in order to validate SVC-CI in the setting of elevated PEEP. A PEEP level of 8-10cmH2O will be applied for 1 minute prior to every measurement of SVC-CI. Then the previous PEEP level will be reinstated.

06

What researchers measure

Primary outcomes

  1. Fluid responsiveness

    Fluid responsiveness was defined as an increase of 10% or more of cardiac output (CO) following an administered 250ml fluid bolus. Changes in CO will be estimated using changes in left ventricle outflow tract velocity time integral (LVOT-VTI) assessed by transesophageal echocardiography to avoid errors associated with measuring LVOT area, which is necessary to calculate CO.

    Time frame: Directly after infusing fluid bolus.

07

Study locations

1 site
  • Opole University Hospital
    Opole, 45-401, Poland
08

References and documents

Individual participant data

Plan to share: No — The data will be shared in open access, however no plan has been designed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Nov 2025, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Jan 3, 2024
StartActual
Jan 3, 2024
Primary completionActual
Nov 17, 2025
CompletionActual
Nov 18, 2025
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06188039
Lead sponsor
Uniwersytecki Szpital Kliniczny w Opolu
Responsible party
Tomasz Królicki, MD PhD (Principal Investigator, Uniwersytecki Szpital Kliniczny w Opolu) — Principal investigator
First posted
Jan 3, 2024
Start date
Jan 3, 2024
Primary completion
Nov 17, 2025
Completion
Nov 18, 2025
Last update
Jan 6, 2026

Study contacts

Tomasz Królicki, MD, PhD
study chair · Uniwersytecki Szpital Kliniczny w Opolu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion